High Signal Podcasts Evidence ledger
Method
Browse
← Back to evidence

Evidence receipt / commitment

Published · transcript-backed

Ben Gilbert: commitment

22 Jan 2024 Acquired Novo Nordisk (Ozempic)

“Later, we will talk about why margins are actually not the most interesting measure to look at, but it's worth knowing them, because we talk about them on every other episode.”

— Ben Gilbert

Source trail

Everything needed to verify it.

Speaker
Ben Gilbert
Attribution
Verified speaker
Claim type
commitment
Recorded
22 Jan 2024
Publisher
Acquired

Transcript context

…Yeah, totally wild. Insulin has become, to your point, still a part of the business, a smaller share of the business. Again, this is of revenue, not of profits. But 22% of their revenue today comes from Insulin. That leaves about 9% from the other efforts that they're putting energy into, rare diseases, things like hemophilia. They continue to be a ridiculously concentrated company. They make about $10 billion a year in net income. They're also a very, very profitable company among the most profitable and all of pharma, the 55,000 employees. So it's a huge international company at this point. I want to talk briefly about margins. Later, we will talk about why margins are actually not the most interesting measure to look at, but it's worth knowing them, because we talk about them on every other episode. Gross margins are better than software. They run about 84%. Lilly is also a very high margin company running about 80%. For context, Microsoft It has a gross margin of 70% and Google is 56%. How is Google's gross margin 56%? They must be stuffing a lot of other revenue besides search into the top line.…

Stored transcript either side of the excerpt. The highlighted words are the published quote; the surrounding text is unedited source, never generated.

Search evidence